Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology

Lih Fen Lue, Yu Min Kuo, Marwan Sabbagh

研究成果: Review article

1 引文 (Scopus)

摘要

New super-sensitive biomarker assay platforms for measuring Alzheimer’s disease (AD) core pathological markers in plasma have recently been developed and tested. Research findings from these technologies offer promising evidence for identifying the earliest stages of AD and correlating them with brain pathological progression. Here, we review findings using immunomagnetic reduction, one of these ultrasensitive technologies. The principles, technology and assays developed, along with selected published findings will be discussed. The major findings from this technology were significant increases of amyloid beta (Aβ) 42 and total tau (t-tau) levels in subjects clinically diagnosed with early AD when compared with cognitively normal control (NC) subjects. The composite marker of the product of Aβ42 and t-tau discriminated subjects with early AD from NC subjects with high accuracy. The potential of this technology for the purpose of early or preclinical disease stage detection has yet to be explored in subjects who have also been assessed with brain imaging and cerebrospinal fluid AD core biomarker measurements.

原文English
頁(從 - 到)95-111
頁數17
期刊Neurology and Therapy
8
DOIs
出版狀態Published - 2019 十二月 1

指紋

Alzheimer Disease
Biomarkers
Technology
Amyloid
Neuroimaging
Cerebrospinal Fluid
Brain
Research

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

引用此文

@article{fdf48ee64463415bba8adb0971826caa,
title = "Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology",
abstract = "New super-sensitive biomarker assay platforms for measuring Alzheimer’s disease (AD) core pathological markers in plasma have recently been developed and tested. Research findings from these technologies offer promising evidence for identifying the earliest stages of AD and correlating them with brain pathological progression. Here, we review findings using immunomagnetic reduction, one of these ultrasensitive technologies. The principles, technology and assays developed, along with selected published findings will be discussed. The major findings from this technology were significant increases of amyloid beta (Aβ) 42 and total tau (t-tau) levels in subjects clinically diagnosed with early AD when compared with cognitively normal control (NC) subjects. The composite marker of the product of Aβ42 and t-tau discriminated subjects with early AD from NC subjects with high accuracy. The potential of this technology for the purpose of early or preclinical disease stage detection has yet to be explored in subjects who have also been assessed with brain imaging and cerebrospinal fluid AD core biomarker measurements.",
author = "Lue, {Lih Fen} and Kuo, {Yu Min} and Marwan Sabbagh",
year = "2019",
month = "12",
day = "1",
doi = "10.1007/s40120-019-00167-2",
language = "English",
volume = "8",
pages = "95--111",
journal = "Neurology and Therapy",
issn = "2193-8253",
publisher = "Springer Healthcare",

}

TY - JOUR

T1 - Advance in Plasma AD Core Biomarker Development

T2 - Current Findings from Immunomagnetic Reduction-Based SQUID Technology

AU - Lue, Lih Fen

AU - Kuo, Yu Min

AU - Sabbagh, Marwan

PY - 2019/12/1

Y1 - 2019/12/1

N2 - New super-sensitive biomarker assay platforms for measuring Alzheimer’s disease (AD) core pathological markers in plasma have recently been developed and tested. Research findings from these technologies offer promising evidence for identifying the earliest stages of AD and correlating them with brain pathological progression. Here, we review findings using immunomagnetic reduction, one of these ultrasensitive technologies. The principles, technology and assays developed, along with selected published findings will be discussed. The major findings from this technology were significant increases of amyloid beta (Aβ) 42 and total tau (t-tau) levels in subjects clinically diagnosed with early AD when compared with cognitively normal control (NC) subjects. The composite marker of the product of Aβ42 and t-tau discriminated subjects with early AD from NC subjects with high accuracy. The potential of this technology for the purpose of early or preclinical disease stage detection has yet to be explored in subjects who have also been assessed with brain imaging and cerebrospinal fluid AD core biomarker measurements.

AB - New super-sensitive biomarker assay platforms for measuring Alzheimer’s disease (AD) core pathological markers in plasma have recently been developed and tested. Research findings from these technologies offer promising evidence for identifying the earliest stages of AD and correlating them with brain pathological progression. Here, we review findings using immunomagnetic reduction, one of these ultrasensitive technologies. The principles, technology and assays developed, along with selected published findings will be discussed. The major findings from this technology were significant increases of amyloid beta (Aβ) 42 and total tau (t-tau) levels in subjects clinically diagnosed with early AD when compared with cognitively normal control (NC) subjects. The composite marker of the product of Aβ42 and t-tau discriminated subjects with early AD from NC subjects with high accuracy. The potential of this technology for the purpose of early or preclinical disease stage detection has yet to be explored in subjects who have also been assessed with brain imaging and cerebrospinal fluid AD core biomarker measurements.

UR - http://www.scopus.com/inward/record.url?scp=85076344266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076344266&partnerID=8YFLogxK

U2 - 10.1007/s40120-019-00167-2

DO - 10.1007/s40120-019-00167-2

M3 - Review article

AN - SCOPUS:85076344266

VL - 8

SP - 95

EP - 111

JO - Neurology and Therapy

JF - Neurology and Therapy

SN - 2193-8253

ER -